United States Securities and Exchange Commission · EDGAR
Accession 0001213900-25-102529
Polaryx Therapeutics, Inc.
Progress updateAt the close of the offering, the issuer closed on $23,014.60 and 35,301 number of securities.
A
The Offering
as disclosed in this filing
Common Stock
$0.70
$15,000
$5,000,000
March 31, 2026
Expired 75 days ago
$0max $5,000,000
Target is 0% of the maximum. Over-subscriptions accepted.
B
Financial Condition
two fiscal years, as filed
Pre-revenueBurn increasing11 employees
| Line item | Most recent FY | Prior FY | Δ |
|---|
| Revenue | 0 | 0 | — |
| Cost of goods sold | 0 | 0 | — |
| Net income | (30,356,000) | (3,779,000) | ▼ burn |
| Total assets | 5,001,000 | 2,315,000 | ▲ 116% |
| Cash & equivalents | 4,621,000 | 2,000 | ▲ |
| Accounts receivable | 0 | 0 | — |
| Short-term debt | 0 | 128,000 | ▼ 100% |
| Long-term debt | 0 | 0 | — |
| Taxes paid | 0 | 0 | — |
Figures in USD as reported by the issuer. Securities offered in all 50 states.
C
Campaign Timeline
file 020-36323 · all filings under this campaign
Loading campaign history…